TY - JOUR
T1 - Glucocorticoids and joint destruction in rheumatoid arthritis
AU - Fries, James F.
AU - Singh, Gurkirpal
AU - Porter, Duncan
AU - Deodhar, A. A.
AU - Woolf, A. D.
AU - Kirwan, John R.
PY - 1995/12/7
Y1 - 1995/12/7
N2 - To the Editor: Kirwan et al. (July 20 issue)1 found that “in patients with early, active rheumatoid arthritis, prednisolone (7.5 mg daily) given for two years in addition to other treatments substantially reduced the rate of radiologically detected progression of disease.” Rheumatoid arthritis is a disease that lasts 20 to 25 years, and the ultimate goal of a therapeutic strategy is to reduce the cumulative pain, disability, side effects, economic impact, and mortality over the course of the illness. Long-term, prospective observational studies of prednisone use show very disquieting results. With the use of average prednisone doses (6.9 mg per.
AB - To the Editor: Kirwan et al. (July 20 issue)1 found that “in patients with early, active rheumatoid arthritis, prednisolone (7.5 mg daily) given for two years in addition to other treatments substantially reduced the rate of radiologically detected progression of disease.” Rheumatoid arthritis is a disease that lasts 20 to 25 years, and the ultimate goal of a therapeutic strategy is to reduce the cumulative pain, disability, side effects, economic impact, and mortality over the course of the illness. Long-term, prospective observational studies of prednisone use show very disquieting results. With the use of average prednisone doses (6.9 mg per.
UR - http://www.scopus.com/inward/record.url?scp=0028810392&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028810392&partnerID=8YFLogxK
U2 - 10.1056/NEJM199512073332314
DO - 10.1056/NEJM199512073332314
M3 - Letter
C2 - 7477183
AN - SCOPUS:0028810392
SN - 0028-4793
VL - 333
SP - 1569
EP - 1570
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 23
ER -